Who are Treatment regimens for MDR-TB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BDL regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-regimens-for-mdr-tb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Treatment regimens for MDR-TB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment regimens for MDR-TB (Treatment regimens for MDR-TB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-tuberculous combination therapy. Area: Infectious Disease.

marketed Anti-tuberculous combination therapy Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Treatment regimens for MDR-TB (Treatment regimens for MDR-TB) — Shanghai Pulmonary Hospital, Shanghai, China. MDR-TB treatment regimens combine multiple anti-tuberculous drugs to overcome drug resistance and eliminate Mycobacterium tuberculosis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treatment regimens for MDR-TB TARGET	Treatment regimens for MDR-TB	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Anti-tuberculous combination therapy
BDL regimen	BDL regimen	Beijing Chest Hospital	marketed	Anti-tuberculous combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-tuberculous combination therapy class)

Beijing Chest Hospital · 1 drug in this class
Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment regimens for MDR-TB — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-regimens-for-mdr-tb. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab